Main > > >ESOPHAGEAL CANCER. *

TREAT.: NivoluMAb
[SQUAMOUS>METASTATIC>RECURRENT (R)]
EU Approval Date: 2020. 11.24.
JP Approval Date: 2020. 02.21.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2021. 02.14.




TREAT.: PembrolizuMAb.
[SQUAMOUS>METASTATIC>RECURRENT (R)]
2nd Line Treat.>1 Prior Lines Systemic
Therapy.
Whose Tumors Express PD-L1 (CPS ≥10)
as determined by an FDA-approved test.
CN Approval Date: 2020. 06.22.
JP Approval Date: 2020. 08.24.
USA Approval Date: 2019. 07.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.30.


>ESOPHAGEAL CANCER. *'s products
This section has no products